Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse-Reference-Cited by-同舟云学术

Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse

Published:2010-10 Issue:2 Volume:202 Page:101-107
ISSN:0165-4608
Container-title:Cancer Genetics and Cytogenetics
language:en
Short-container-title:Cancer Genetics and Cytogenetics

Author:

Wang Eunice S.,Sait Sheila N.J.,Gold David,Mashtare Terry,Starostik Petr,Ford Laurie Ann,Wetzler Meir,Nowak Norma J.,Deeb George

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Molecular Biology

Reference43 articles.

1. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children’s Leukaemia Working Parties;Grimwade;Blood,1998

2. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461);Byrd;Blood,2002

3. Prognostic index for adult patients with acute myeloid leukemia in first relapse;Breems;J Clin Oncol,2005

4. Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy;Kern;Leukemia,2002

5. Evolution of karyotypes in acute nonlymphocytic leukemia;Testa;Cancer Res,1979

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of bone marrow heterogeneity in NK-AML (M4/M5) based on single-cell RNA sequencing;Experimental Hematology & Oncology;2023-03-06

2. Characterization of The Heterogeneity of Bone Marrow in NK-AML (M4/M5) Based on Single Cell RNA Sequencing;2022-10-26

3. Landscape of T Cells in NK-AML(M4/M5) Revealed by Single-Cell Sequencing;Journal of Leukocyte Biology;2022-03-08

4. Drug interaction (51. New oral anticancer drugs in hematological malignancies and drug interactions);Okayama Igakkai Zasshi (Journal of Okayama Medical Association);2021-08-02

5. Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia;Biomarker Research;2019-09-11